Article

Three Current Ataxia Trials

Learn key information about three trials currently recruiting patients with ataxia.

Characteristics of Episodic Ataxia Syndrome

Study Type: Observational

Age/Gender Requirement: 5 years+ (male/female)

Sponsor: Office of Rare Diseases

Purpose: To better characterize episodic ataxia and disease progression, hopefully to help direct development of future treatments, as the underlying cause of the condition is only partially understood, no treatments are currently established, and there is little known regarding the association between episodic ataxia clinical features and genetic basis.

Click here to access this third-party resource

Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10

Type: Observational

Age/Gender Requirement: Not Listed (male/female)

Sponsor: National Institute of Neurological Disorders and Stroke

Purpose: To clinically “evaluate members from families with dominantly inherited ataxias and collect blood samples for detailed molecular studies” and to perform “detailed clinical evaluations on patients with recessively inherited ataxias.”

Click here to access this third-party resource.

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Study Type: Observational

Age/Gender Requirement: 6 years+ (male/female)

Sponsor: University of Florida

Purpose: To bring “together a group of experts in the field of” spinocerebellar ataxias in order to better understand how the disease progresses, the best ways to measure progression, and whether genes aside from that which is abnormal in spinocerebellar ataxias have an effect on how the disease behaves.

Click here to access thsi third-party resource.

Related Videos
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Stephanie Nahas, MD, MSEd | Credit: Jefferson Health
John Harsh, PhD: Exploring Once-Nightly Sodium Oxybate Therapy for Narcolepsy
John Harsh, PhD
© 2024 MJH Life Sciences

All rights reserved.